On June 4, Medtronic rose 3.63% in regular trading, trading at $82.09/share, with trading volume of $175 million. The stock continued its strong momentum following the prior session's earnings-driven surge.

On the news front, Medtronic reported fiscal Q4 revenue of $9.807 billion, exceeding the consensus estimate of $9.635 billion, and achieved its strongest annual revenue growth in a decade. The core Cardiovascular Portfolio delivered 13.8% year-over-year growth, fueled by robust demand for its pulsed field ablation product suite. Additionally, BTIG upgraded Medtronic from Neutral to Buy with a $90 price target, further bolstering market sentiment. The company also announced strategic investments in two intracardiac echocardiography catheter companies to support cardiac ablation portfolio expansion, and filed a 510(K) application to expand its Hugo robotic-assisted surgery system into general surgery and gynecology in the U.S.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)